Tag: sentinelLymphNode

News

09/16/12

Axillary node dissection unnecessary for some despite micrometastases

08/12/12

Lymph node negative ER-/PR- BC has less favorable prognosis

11/19/10

Factors predicting upstaging from DCIS to invasive BC at biopsy

10/03/10

Lobular breast cancer micrometastases may be classified incorrectly

09/08/10

Sentinel node micrometastases do not reduce breast cancer survival

02/28/10

Does air travel increase lymphedema in breast cancer survivors?

Studies

• Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy? Cite
  Record SM, Thomas SM, Dalton J, van den Bruele AB, Chiba A, DiLalla G, et al. Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16106-x
• Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis Cite
  Parpex G, Ottaviani M, Lorphelin H, Mezzadri M, Marchand E, Cahen-Doidy L, et al. Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis. The Breast. Elsevier BV; 2024;:103703 10.1016/j.breast.2024.103703
• A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer Cite
  Chung AP, Dang CM, Karlan SR, Amersi FF, Phillips EM, Boyle MK, et al. A Prospective Study of Sentinel Node Biopsy Omission in Women Age ≥ 65 Years with ER+ Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-15000-w
• Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns Cite
  Goldhaber NH, O’Keefe T, Kang J, Douglas S, Blair SL. Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13886-6
• Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer Cite
  Ye L, Rünger D, Angarita SA, Hadaya J, Baker JL, Lee MK, et al. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06581-9
• Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Cite
  Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, et al. Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-021-11140-5
• Oncologists’ perspectives on omission of sentinel lymph node biopsy in women >70 years with early-stage hormone receptor-positive breast cancer. Cite
  Minami CA, Bryan AF, Revette AC, Freedman RA, King TA, Mittendorf EA. Oncologists’ perspectives on omission of sentinel lymph node biopsy in women >70 years with early-stage hormone receptor-positive breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021; 39:48-48 10.1200/jco.2020.39.28_suppl.48
• Impact of Choosing Wisely Recommendations on Sentinel Lymph Node Biopsy and Postoperative Radiation Rates in Women Over Age 70 Years with Hormone-Positive Breast Cancer Cite
  Thompson J, Le J, Hop A, Melnik M, Paulson J, Wright GP. Impact of Choosing Wisely Recommendations on Sentinel Lymph Node Biopsy and Postoperative Radiation Rates in Women Over Age 70 Years with Hormone-Positive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10460-w
• Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy Cite
  McKevitt E, Cheifetz R, DeVries K, Laws A, Warburton R, Gondara L, et al. Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-09839-6
• Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer? Cite
  Sun J, Mathias BJ, Sun W, Fulp WJ, Zhou J, Laronga C, et al. Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 28:320-329 10.1245/s10434-020-08759-1
• De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study Cite
  Simons JM, Koppert LB, Luiten EJT, van der Pol CC, Samiei S, de Wilt JHW, et al. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:725-733 10.1007/s10549-020-05589-3
• Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers Cite
  Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, et al. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:735-745 10.1007/s10549-020-05565-x
• Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ Cite
  Hung P, Wang S, Killelea BK, Mougalian SS, Evans SB, Sedghi T, et al. Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ. JNCI Cancer Spectrum. Oxford University Press (OUP); 2019; 3 10.1093/jncics/pkz052
• Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified? Cite
  Sorrentino L, Sartani A, Bossi D, Amadori R, Nebuloni M, Truffi M, et al. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?. The Breast Journal. Wiley; 2017; 24:325-333 10.1111/tbj.12928
• Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Cite
  Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:561-564 10.1200/jco.2016.71.0947
• The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study Cite
  Holm-Rasmussen EV, Jensen M, Balslev E, Kroman N, Tvedskov TF. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. European Journal of Cancer. Elsevier BV; 2017; 87:1-9 10.1016/j.ejca.2017.09.037
• Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Cite
  Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. American Medical Association (AMA); 2017; 318:918 10.1001/jama.2017.11470
• Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer Cite
  DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, et al. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 18:e73-e77 10.1016/j.clbc.2017.06.014
• Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy Cite
  Nogi H, Uchida K, Mimoto R, Kamio M, Shioya H, Toriumi Y, et al. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. Clinical Breast Cancer. Elsevier BV; 2017; 17:644-649 10.1016/j.clbc.2017.05.002
• The clinical implication of the number of lymph nodes harvested during sentinel lymph node biopsy and its effects on survival outcome in patients with node-negative breast cancer Cite
  Kim MK, Park HS, Kim JY, Kim S, Nam S, Park S, et al. The clinical implication of the number of lymph nodes harvested during sentinel lymph node biopsy and its effects on survival outcome in patients with node-negative breast cancer. The American Journal of Surgery. Elsevier BV; 2017; 214:726-732 10.1016/j.amjsurg.2016.10.019
• Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy Cite
  van Roozendaal LM, Goorts B, Klinkert M, Keymeulen KBMI, De Vries B, Strobbe LJA, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:517-525 10.1007/s10549-016-3783-2
• Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study Cite
  de Boniface J, Frisell J, Bergkvist L, Andersson Y. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. British Journal of Surgery. Oxford University Press (OUP); 2017; 104:238-247 10.1002/bjs.10411
• Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy Cite
  Navarro-Rodríguez E, Díaz-Jiménez N, Ruiz-Rabelo J, Gómez-Luque I, Bascuñana-Estudillo G, Rioja-Torres P, et al. Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy. Clinical Breast Cancer. Elsevier BV; 2016; 16:e181-e186 10.1016/j.clbc.2016.06.013
• Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Cite
  El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. The American Journal of Surgery. Elsevier BV; 2016; 212:969-981 10.1016/j.amjsurg.2016.07.018
• The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance Cite
  Youssef MM, Cameron D, Pucher PH, Olsen S, Ferguson D. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance. The Breast. Elsevier BV; 2016; 30:101-104 10.1016/j.breast.2016.09.005
• Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Cite
  El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. The American Journal of Surgery. Elsevier BV; 2016; 212:969-981 10.1016/j.amjsurg.2016.07.018
• Long term results of treatment of breast cancer without axillary surgery – Predicting a SOUND approach? Cite
  O'Connell R, Rusby J, Stamp G, Conway A, Roche N, Barry P, et al. Long term results of treatment of breast cancer without axillary surgery – Predicting a SOUND approach?. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:942-948 10.1016/j.ejso.2016.03.027
• Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer Cite
  Truin W, Roumen RM, Siesling S, van der Heiden-van der Loo M, Lobbezoo DJ, Tjan-Heijnen VC, et al. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e75-e82 10.1016/j.clbc.2016.03.007
• Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial Cite
  Gentilini O, Botteri E, Dadda P, Sangalli C, Boccardo C, Peradze N, et al. Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:685-689 10.1016/j.ejso.2016.01.020
• Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta‐Analysis Cite
  Nagaraja V, Edirimanne S, Eslick GD. Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta‐Analysis. The Breast Journal. Wiley; 2016; 22:158-165 10.1111/tbj.12549
• Impact of sentinel node tumor burden on outcome of invasive breast cancer patients Cite
  Meattini I, Desideri I, Saieva C, Francolini G, Scotti V, Bonomo P, et al. Impact of sentinel node tumor burden on outcome of invasive breast cancer patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:1195-1202 10.1016/j.ejso.2014.08.471
• Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients Cite
  Martelli G, Boracchi P, Orenti A, Lozza L, Maugeri I, Vetrella G, et al. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:805-812 10.1016/j.ejso.2014.03.029
• Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database Cite
  Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, et al. Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e89778 10.1371/journal.pone.0089778
• Upper Limb Physical Function and Adverse Effects After Breast Cancer Surgery: A Prospective 2.5-Year Follow-Up Study and Preoperative Measures Cite
  Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA. Upper Limb Physical Function and Adverse Effects After Breast Cancer Surgery: A Prospective 2.5-Year Follow-Up Study and Preoperative Measures. Archives of Physical Medicine and Rehabilitation. Elsevier BV; 2014; 95:875-881 10.1016/j.apmr.2013.12.015
• Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000 Cite
  Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 20:120-127 10.1245/s10434-012-2569-y
• Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection Cite
  Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, et al. Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 256:428-436 10.1097/sla.0b013e3182654494
• Effectiveness of Sentinel Lymph Node Intraoperative Examination in 753 Women With Breast Cancer Cite
  Taffurelli M, Montroni I, Santini D, Fiacchi M, Zanotti S, Ugolini G, et al. Effectiveness of Sentinel Lymph Node Intraoperative Examination in 753 Women With Breast Cancer. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 255:976-980 10.1097/sla.0b013e31824def4e
• Axillary node staging for microinvasive breast cancer: Is it justified? Cite
  Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: Is it justified?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:7-7 10.1200/jco.2011.29.27_suppl.7
• Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32. Cite
  Julian TB, Anderson SJ, Mamounas EP, Krag DN, Weaver D, Ashikaga T, et al. Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:80-80 10.1200/jco.2011.29.27_suppl.80
• Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer Cite
  Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, et al. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. Wiley; 2011; 118:1507-1514 10.1002/cncr.26458
• Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer Cite
  Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, et al. Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2628-2634 10.1200/jco.2010.32.1877
• A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression Cite
  Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. The American Journal of Surgery. Elsevier BV; 2011; 201:692-694 10.1016/j.amjsurg.2010.02.015
• Effect of Occult Metastases on Survival in Node-Negative Breast Cancer Cite
  Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 364:412-421 10.1056/nejmoa1008108
• Risk Factors for Invasive Breast Cancer When Core Needle Biopsy Shows Ductal Carcinoma In Situ Cite
  Kurniawan ED. Risk Factors for Invasive Breast Cancer When Core Needle Biopsy Shows Ductal Carcinoma In Situ. Archives of Surgery. American Medical Association (AMA); 2010; 145:1098 10.1001/archsurg.2010.243
• Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma Cite
  Apple SK, Moatamed NA, Finck RH, Sullivan PS. Accurate classification of sentinel lymph node metastases in patients with lobular breast carcinoma. The Breast. Elsevier BV; 2010; 19:360-364 10.1016/j.breast.2010.02.010
• Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study Cite
  Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, Coebergh JWW, Roumen RM, Nolthenius-Puylaert MCT, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:195-203 10.1007/s10549-010-1086-6
• Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence Cite
  Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, et al. Avoiding Axillary Treatment in Sentinel Lymph Node Micrometastases of Breast Cancer: A Prospective Analysis of Axillary or Distant Recurrence. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2009; 17:772-777 10.1245/s10434-009-0804-y
• Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases Cite
  de Boer M, van Dijck JAAM, Bult P, Borm GF, Tjan-Heijnen VCG. Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:410-425 10.1093/jnci/djq008
• Obesity is a Risk Factor for Developing Postoperative Lymphedema in Breast Cancer Patients Cite
  Helyer LK, Varnic M, Le LW, Leong W, McCready D. Obesity is a Risk Factor for Developing Postoperative Lymphedema in Breast Cancer Patients. The Breast Journal. Wiley; 2010; 16:48-54 10.1111/j.1524-4741.2009.00855.x
• Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes Cite
  Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:170-178 10.1093/jnci/djp482
• Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy Cite
  Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, et al. Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy. Journal of the American College of Surgeons. Elsevier BV; 2009; 209:746-752 10.1016/j.jamcollsurg.2009.08.010
• The identification and treatment of isolated tumor cells reflect disparities in the delivery of breast cancer care Cite
  Tan JT, Bagnell M, Morgan JW, Wong JH, Roy-Chowdhury S, Lum SS. The identification and treatment of isolated tumor cells reflect disparities in the delivery of breast cancer care. The American Journal of Surgery. Elsevier BV; 2009; 198:508-510 10.1016/j.amjsurg.2009.07.001